Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PODOMOUNT-pFSGS
NCT07220083Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 40
01
Overview
A Phase 3 trial of apecotrep in focal segmental glomerulosclerosis (FSGS), sponsored by Boehringer Ingelheim. Started Feb 2026; status: recruiting.
02
Drugs
apecotrep
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT07220083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07220083.